Peer-reviewed veterinary case report
Comparing side effects of two doxorubicin doses in cats
By Reiman, Rachel A et al.·Published in Journal of feline medicine and surgery·2008·Department of Veterinary Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A comparison of toxicity of two dosing schemes for doxorubicin in the cat.
- Species:
- cat
Plain-English summary
A group of cats with tumors received either a standard dose or a higher dose of doxorubicin, a chemotherapy drug, to see which caused more side effects. While the higher dose led to lower neutrophil counts (a type of white blood cell), no other significant differences in side effects were found between the two groups. This suggests that giving a higher dose of doxorubicin may not increase the risk of toxicity in cats. More research is needed to find the best dosing for this treatment.
People also search for: cat cancer treatment doxorubicin side effects · doxorubicin dosage for cats · cat chemotherapy weight loss
Abstract
Doxorubicin is a commonly used and effective treatment for a variety of tumors in both people and cats. However, the use of this drug in cats has been associated with side effects such as renal injury, myelosuppression, anorexia, and weight loss. The goal of this study was to compare the toxicities associated with two dosing schemes for doxorubicin in tumor-bearing cats. Group A cats received 1mg/kg of doxorubicin, while group B cats received 25mg/m2 of doxorubicin plus 22ml lactated Ringer's solution per kilogram body weight subcutaneously. Toxicities were evaluated using laboratory data, physical examination, and history, and were graded using a standardized scale and compared between groups. Post-treatment neutrophil counts were significantly lower among cats in group B compared to cats in group A (P< or =0.001), although complete blood counts were not evaluated at identical intervals in all cases. No other significant differences in the type, frequency or severity of clinical or laboratory toxicities were noted between groups, and no episodes of sepsis were recognized in either group. The results of this study suggest that higher doses of doxorubicin may not be associated with an increased risk of toxicity in the cat. Additional studies are still indicated to determine optimal dosing for doxorubicin in this species.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/18434224/